Lupin Ltd, India’s third largest drug maker, on Tuesday said it has agreed to buy a portfolio of 21 generic brands from Osaka-based Shionogi & Co. Ltd for $150 million, to strengthen its presence in the world’s second largest pharmaceutical market.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
